Q2/FY26
$ARM had a triple beat (revenue/EPS/Q3 guide) and got mostly upward revisions. Records all over the place. Stock sits around ~$158.
• Evercore ISI: PT $215 (from $178), Outperform
• KeyBanc: PT $200 (from $190), Overweight
• TD Cowen: PT $190 (from $175), Buy
• Mizuho: PT $190 (from $180), Outperform
• JPMorgan: PT $180 (from $175), Overweight
• UBS: PT $195 (from $200), Buy (trim)
• Needham: Hold (no PT change)
Look at the share gains in the image 👇
The analyst Q&A focused on:
•Concerns around Arm’s China exposure, licensing pipeline, and deal cycle timing.
•Data center and cloud segment revenue mix and future growth.
•Rising operating expenses and R&D investment strategy.
•Adoption rate of Armv9 architecture and higher royalty rates.
•Strategic partnerships, with Meta highlighted for AI infrastructure collaboration.
•Volatility in licensing revenue, with emphasis on deal lumpiness and Q4 expectations.
•Expansion into ASICs, chiplets, and complete SoC solutions, including DreamBig Semiconductor acquisition.
•Scrutiny over SoftBank-related party revenue and its impact on overall results.
I am most interested in learning about any ASICs, chipsets and SOCs.